92 related articles for article (PubMed ID: 6145427)
1. Results of a multicenter AMDP study with fluperlapine in schizophrenic patients.
Woggon B; Heinrich K; Küfferle B; Müller-Oerlinghausen B; Pöldinger W; Rüther E; Schied HW
Arzneimittelforschung; 1984; 34(1A):122-4. PubMed ID: 6145427
[TBL] [Abstract][Full Text] [Related]
2. Fluperlapine in 104 schizophrenic patients. Open multicenter trial.
Fischer-Cornelssen KA
Arzneimittelforschung; 1984; 34(1A):125-30. PubMed ID: 6145428
[TBL] [Abstract][Full Text] [Related]
3. A short survey on untoward effects of fluperlapine.
Müller-Oerlinghausen B
Arzneimittelforschung; 1984; 34(1A):131-4. PubMed ID: 6145429
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
[TBL] [Abstract][Full Text] [Related]
5. Pharmaco-EEG studies with fluperlapine.
Matejcek M; Neff G; Tjeerdsma H; Krebs E
Arzneimittelforschung; 1984; 34(1A):114-20. PubMed ID: 6145426
[TBL] [Abstract][Full Text] [Related]
6. Amisulpride--an open clinical study of a new benzamide in schizophrenic patients.
Mann K; Bartels M; Bauer H; Gaertner HJ
Pharmacopsychiatry; 1984 Jul; 17(4):111-5. PubMed ID: 6147865
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
[TBL] [Abstract][Full Text] [Related]
8. The AMDP system in international clinical trials: a double-blind comparison of fluperlapine and haloperidol.
Woggon B; Linden M; Beckmann H; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pflug B; Schied HW
Psychopharmacol Bull; 1986; 22(1):47-51. PubMed ID: 2873619
[No Abstract] [Full Text] [Related]
9. Differential effects of a new dibenzo-epine neuroleptic compared with haloperidol. Results of an open and crossover study.
Mann K; Bartels M; Gärtner HJ; Schied HW; Wagner W; Heimann H
Pharmacopsychiatry; 1987 Jul; 20(4):155-9. PubMed ID: 2886997
[TBL] [Abstract][Full Text] [Related]
10. Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764).
Floru L; Tegeler J
Arzneimittelforschung; 1978; 28(2):341-4. PubMed ID: 25071
[TBL] [Abstract][Full Text] [Related]
11. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
12. [Penfluridol. Results of a year-long clinical trial].
Woggon B
Int Pharmacopsychiatry; 1978; 13(1):1-15. PubMed ID: 342435
[TBL] [Abstract][Full Text] [Related]
13. Depressive symptoms and schizophrenia a psychopharmacological approach.
Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
[TBL] [Abstract][Full Text] [Related]
14. [Long-term clinical experience with clozapine].
Gelly F; Chambon O; Marie-Cardine M
Encephale; 1997; 23(5):385-96. PubMed ID: 9453932
[TBL] [Abstract][Full Text] [Related]
15. [Clinical effects of clozapine: effect on negative symptoms].
Llorca PM; Lançon C; Auquier P; Bougerol T
Encephale; 1996; 22(4):287-92. PubMed ID: 9035984
[TBL] [Abstract][Full Text] [Related]
16. The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual care.
Ritsner MS; Yorkov V; Ratner Y; Soifer P; Gibel A
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1470-7. PubMed ID: 17669573
[TBL] [Abstract][Full Text] [Related]
17. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
18. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
19. Do neuroleptics cause depression?
Roy A
Biol Psychiatry; 1984 May; 19(5):777-81. PubMed ID: 6145454
[TBL] [Abstract][Full Text] [Related]
20. [Schizophrenic with obsessive-compulsive disorder or symptoms].
Doubremelle C; Millet B; Olie JP
Encephale; 2000; 26(2):81-8. PubMed ID: 10858921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
